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Age- and Lesion-Related Comorbidity Burden Among US Adults With
Congenital Heart Disease: A Population-Based Study
Anushree Agarwal, MD; Robert Thombley, MS; Craig S. Broberg, MD; Ian S. Harris, MD; Elyse Foster, MD; Vaikom S. Mahadevan, MD;
Anitha John, MD, PhD; Eric Vittinghoff, PhD; Greg M. Marcus, MD, MAS; R. Adams Dudley, MD, MBA
Background-—As patients with congenital heart disease (CHD) are living longer, understanding the comorbidities they develop as
they age is increasingly important. However, there are no published population-based estimates of the comorbidity burden among
the US adult patients with CHD.
Methods and Results-—Using the IBM MarketScan commercial claims database from 2010 to 2016, we identified adults aged ≥18
years with CHD and 2 full years of continuous enrollment. These were frequency matched with adults without CHD within
categories jointly defined by age, sex, and dates of enrollment in the database. A total of 40 127 patients with CHD met the
inclusion criteria (mean [SD] age, 36.8 [14.6] years; and 48.2% were women). Adults with CHD were nearly twice as likely to have
any comorbidity than those without CHD (P<0.001). After adjusting for covariates, patients with CHD had a higher prevalence risk
ratio for “previously recognized to be common in CHD” (risk ratio, 9.41; 95% CI, 7.99–11.1), “other cardiovascular” (risk ratio, 1.73;
95% CI, 1.66–1.80), and “noncardiovascular” (risk ratio, 1.47; 95% CI, 1.41–1.52) comorbidities. After adjusting for covariates and
considering interaction with age, patients with severe CHD had higher risks of previously recognized to be common in CHD and
lower risks of other cardiovascular comorbidities than age-stratified patients with nonsevere CHD. For noncardiovascular
comorbidities, the risk was higher among patients with severe than nonsevere CHD before, but not after, the age of 40 years.
Conclusions-—Our data underscore the unique clinical needs of adults with CHD compared with their peers. Clinicians caring for
CHD may want to use a multidisciplinary approach, including building close collaborations with internists and specialists, to help
provide appropriate care for the highly prevalent noncardiovascular comorbidities. ( J Am Heart Assoc. 2019;8:e013450. DOI:
10.1161/JAHA.119.013450.)
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C ongenital heart disease (CHD) is the most common birthdefect.1 It is estimated that two thirds of the estimated
2.4 million patients with CHD in the United States are now
adults.2–4 The physicians of aging patients with CHD not only
face the challenge of managing long-term sequelae related to
CHD lesions (like heart failure and arrhythmias) but may also
be asked to manage comorbidities these patients acquire as
they age (like coronary artery disease [CAD] and hyperlipi-
demia) and those that affect organs other than the heart (like
renal failure and liver failure).5–7
Prior studies in the United States from single centers8–10
or inpatient databases11,12 have reported comorbidity rates
among patients with CHD. However, single-center studies
have small samples and may be affected by referral bias,
whereas inpatient databases only include the sickest patients,
so provide biased estimates of population-level comorbidity
prevalence. Recently, population-based estimates of rates of
comorbidities in adolescents with CHD from 3 US sites were
reported,13 but similar data about adults are not available.
Although some non–US-based population estimates of the
comorbidity burden have been published,6,14 extrapolating
these to the diverse US population is suboptimal.
To understand the burden of comorbidities among US
patients with CHD, we used a large national cohort of patients
with commercial insurance (1) to provide population-based
estimates of the rates of “previously recognized to be common
in CHD,” “other cardiovascular,” and “noncardiovascular”
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comorbidities in the population with CHD and (2) to compare
these rates with the rates observed in age-, sex-, and dates of
enrollment–matched non-CHD controls.
Methods
All the data used for this study belong to the IBM MarketScan
Commercial Database, and they should be contacted directly
for any data requests.
Setting and Data Sources
We used Health Insurance Portability and Accountability Act–
compliant deidentified patient-level inpatient and outpatient
claims data from the IBM MarketScan Commercial Database,
representing the claims of employees and dependents on large
employer health benefit programs between January 1, 2010,
and December 31, 2016. The plans include a variety of fee-for-
service, preferred provider organization, and capitated health
plans. Claims from Medicare, Medicaid, and Workers Compen-
sation were not included.
Study Population
We limited analyses to enrollees, aged 18 to 64 years, who
had at least 2 full years of continuous enrollment. Patients
were identified as having CHD if they had a diagnosis code
for a CHD lesion. The diagnosis codes used were the
International Classification of Diseases, Ninth Revision (ICD-
9), and the International Classification of Diseases, Tenth
Revision (ICD-10), codes (see Table 1 in online appendix)
that were used by prior investigators.15–17 Because studies
on adult CHD using ICD-10 codes do not yet exist, we
used forward-backward mapping to determine the ICD-10
codes for patients with CHD.18 If an ICD-9 or ICD-10 code
for CHD was present on any inpatient or outpatient claim
at any billing position during the period of enrollment,
these patients were then considered to have CHD. For
patients with codes for >1 CHD diagnosis, we used the
hierarchical algorithm, proposed by Broberg et al,17 to
designate one condition per patient as his/her principal
CHD diagnosis. As described by Broberg et al17 and like
Burchill et al,19 we excluded ICD-9 and ICD-10 codes that
have lower specificity for CHD, including atrial septal
defect, bicuspid aortic valve, aortic stenosis, and unspec-
ified congenital anomalies. We also excluded any patients
who had pregnancy- or delivery-related claims during the
study period to avoid inclusion of pregnant women with
fetuses affected by CHD.20 The remaining patients with
CHD were categorized on the basis of their anatomic
subgroups into16:
1. Severe CHD: Eisenmenger syndrome (ES),17 hypoplastic
left heart syndrome, common ventricle, transposition of
great arteries, tetralogy of Fallot, truncus arteriosus, and
endocardial cushion defect; and
2. Nonsevere CHD: Ebstein anomaly, coarctation of aorta,
anomalies of the pulmonary artery, anomalies of pul-
monary valve, except pulmonary atresia, anomalies of the
tricuspid valve, ventricular septal defect, patent ductus
arteriosus, unspecified septal defects, anomalies of veins,
subaortic stenosis, and aortic anomalies.
Adult CHD cases were frequency matched to adults
without CHD within categories jointly defined by age, sex,
and starting and ending year of enrollment in the IBM
MarketScan database.
Clinical Perspective
What Is New?
• The present study is the largest population-based study of
congenital heart disease (CHD) and provides novel esti-
mates of prevalence rates of comorbidities among adults
with CHD in the United States.
• In this ambulatory population, patients with CHD had higher
prevalence of comorbidities “previously recognized to be
common in CHD,” “other cardiovascular,” and “noncardio-
vascular” comorbidities when compared with patients
without CHD, even before the age of 40 years.
• We found that patients with Eisenmenger syndrome and
common ventricle had among the highest rates of comor-
bidities; after adjusting for covariates and considering
interaction with age, patients with severe CHD of any age
had higher risks of comorbidities previously recognized to
be common in CHD and lower risks of other cardiovascular
comorbidities than patients with nonsevere CHD, whereas
the risk of noncardiovascular comorbidities was higher
among patients with severe CHD than nonsevere CHD aged
<40 years but not different after the age of 40 years.
What Are the Clinical Implications?
• These estimates of comorbidity prevalence could be used to
plan for the clinical resources patients with CHD are likely to
need.
• Our data suggest that preventive measures for cardiovas-
cular comorbidities should be one of the important areas of
focus in patients with CHD; targeted CHD-specific screening
and treatment protocols need to be developed to address
the high burden of comorbidities among patients with CHD.
• Centers that specialize in CHD care may want to adopt a
multidisciplinary approach, including building close partner-
ships with primary care physicians and specialists, to
address the noncardiovascular comorbidities we found to be
prevalent among patients with CHD.
DOI: 10.1161/JAHA.119.013450 Journal of the American Heart Association 2
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Comorbidities
Several tools are available to identify comorbidities in
administrative data.21 To estimate comorbidity rates, we
modified the types of comorbidities listed in the Agency for
Healthcare Research and Quality Elixhauser comorbidity
measures.22 We made this modification because the Agency
for Healthcare Research and Quality measure does not
include some conditions that are important in CHD care (eg,
arrhythmias) and to combine some conditions for ease of
presentation (eg, combining diabetes mellitus with and
without complications). First, the revised version of the
Elixhauser comorbidities was modified to obtain 21 condi-
tions. These modifications included the following: excluding
valvular disorders (because patients with CHD often have
valvular problems as their inherent structural abnormality);
combining 2 types of diabetes mellitus (diabetes mellitus with
complication and diabetes mellitus without complication) into
1 condition (diabetes mellitus); combining 2 types of anemia
(blood loss anemia and deficiency anemia) into 1 condition
(anemia); combining neurodegenerative disorders and paral-
ysis into 1 condition (neurologic disorder); combining
psychosis and depression into 1 condition (psychiatric
disorder); combining alcohol and drug use into 1 condition
(substance abuse); and combining all types of tumors, like
lymphoma, metastasis, and solid tumors, into one condition
(any tumor). Finally, 4 conditions were added: CAD (codes
410.x, 414.0x, 414.2x, 414.3x, 414.8x, 414.9x, I21.XX, I22.X,
and I25); stroke (codes 431, 434, 436, 438, I61, I63, I64, and
I69); atrial or ventricular arrhythmias (codes 427.31, 427.32,
I48.0, I48.1, 427.41, 427.42, 427.5, I46.9, I49.01, and
I49.02); and hypercholesterolemia (codes 272.0, 272.2,
272.4, E78.0, E78.2, and E78.4).23,24
In sum, we assessed for the presence of a total of 25
comorbidities. We classified these into 3 categories:
1. Previously recognized to be common in CHD: congestive
heart failure (CHF), arrhythmias, and pulmonary circulation
disorders;
2. Other cardiovascular: hypertension, hypercholesterolemia,
CAD, peripheral vascular disorders, and stroke; and
3. Noncardiovascular: diabetes mellitus, obesity, neurologic
disorder, hypothyroidism, liver disease, peptic ulcer, AIDS,
any tumor, rheumatoid arthritis/collagen vascular disease,
Table 1. Types of CHD Lesions and Their ICD-9 and ICD-10 Codes
Type of Lesion ICD-9 Codes ICD-10 Codes
Severe lesions
Eisenmenger syndrome
(CHD code AND cyanosis)
782.5 PLUS other congenital
code (782.5+745–747)
I27.83 PLUS other congenital
code (I27.83+Q20–Q28)
Hypoplastic left heart syndrome 746.7 Q23.4
Common ventricle 745.3 Q20.4
Transposition complex 745.10, 745.11, 745.12, 745.19 Q20.1, Q20.3, Q20.5, Q20.8
Tetralogy of Fallot 745.2 Q21.3
Truncus arteriosus 745.0 Q20.0
Endocardial cushion defect 745.60, 745.61, 745.69 Q21.2
Nonsevere lesions
Ebstein anomaly 746.2 Q22.5
Aortic coarctation 747.10 Q25.1
Anomalies of the pulmonary artery
(except pulmonary atresia)
747.31, 747.39 Q25.6, Q25.79, Q25.5, Q25.71
Anomalies of the pulmonary valve 746.0, 746.02, 746.09 Q22.1, Q22.2, Q22.3
Anomalies of the tricuspid valve 746.1 Q22.4, Q22.8, Q22.9
Ventricular septal defect 745.4 Q21.0
Patent ductus arteriosus 747.0 Q25.0
Anomalies of veins 747.4, 747.41, 747.42 Q26.2, Q26.3, Q26.9
Unspecified defect of septal closure 745.9 Q21.9
Subaortic stenosis 746.81 Q24.4
Aortic anomalies 747.29 Q25.41, Q25.42, Q25.43, Q25.44, Q25.48, Q25.49
CHD indicates congenital heart disease; ICD-9, International Classification of Diseases, Ninth Revision; ICD-10, International Classification of Diseases, Tenth Revision.
DOI: 10.1161/JAHA.119.013450 Journal of the American Heart Association 3
Comorbidities in ACHD Agarwal et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
coagulopathy, weight loss, fluid and electrolyte disorders,
anemia, renal disease, substance abuse, psychiatric
disorder, and chronic pulmonary disease.
Basic Demographics
Demographic characteristics assessed included age, sex, and
US region. The MarketScan database includes information on
the relationship of the patient to the primary beneficiary
(employee, spouse, child/other, or dependent relation
unknown). We determined whether the patient was the
primary beneficiary (employee).
Statistical Analysis
Continuous variables are summarized by meanSD, and
categorical variables are summarized by percentages.
Student t and Pearson v2 tests were used as appropriate
Figure 1. Anatomical subgroup distribution of the cohort with congenital heart disease, stratified by age
categories into those aged 18 to 40 years (n=32 605; A) and those aged ≥40 years (n=17 642; B). Source:
IBM MarketScan database, 2010 to 2016. Severe lesions are represented in red. CoA indicates coarctation
of aorta; HLHS, hypoplastic left heart syndrome; PA, pulmonary artery; PDA, patent ductus arteriosus; PV,
pulmonary valve; TA, truncus arteriosus; TGA, transposition of great arteries; TOF, tetralogy of Fallot; TV,
tricuspid valve; VSD, ventricular septal defect.
DOI: 10.1161/JAHA.119.013450 Journal of the American Heart Association 4
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to contrast the characteristics of CHD cases and controls.
Poisson regression models with robust SEs were used to
estimate prevalence ratios for comorbidities.25 All regres-
sion analyses were adjusted for age, sex, whether the
patient was the primary beneficiary, start and end year
of enrollment, and region of the United States. Interaction
of age on the association of the presence or absence of
CHD or the type of CHD (severe versus nonsevere) with
comorbidities was studied. Statistical analyses were
performed using STATA/SE software, version 14 (Stata-
Corp).
Certification to use deidentified MarketScan data was
obtained from the University of California, San Francisco,
Committee on Human Research; and the need for informed
consent was waived.
Results
Study Cohort Characteristics
A total of 40 127 CHD cases met our inclusion criteria. Mean
age of the study population was 36.814.6 years, 57.2%
were aged 18 to 40 years, and 48.2% were women. Of all the
patients, 49.4% were primary beneficiaries and 48.9% were
actively employed. Patients with severe CHD constituted
29.9% of the entire CHD population (38.1% for the 18- to 40-
year-old population versus 26.5% of the ≥40-year-old CHD
population; P<0.001). The distribution of patients with CHD
within individual anatomical subgroups for the 2 age cate-
gories is shown in Figure 1.
Comorbidities
Adults with CHD were nearly twice as likely to have a
comorbidity than those without CHD (30.1% versus 13.8% for
18- to 40-year-old patients; 58.1% versus 36.7% for ≥40-year-
old patients; P<0.001). In addition, adults with CHD were also
more likely to have a higher number of comorbidities than
adults without CHD (P<0.001; Figure 2). Each type of
comorbidity (whether previously recognized to be common
in CHD, other cardiovascular, and non cardiovascular) was
more common in patients with CHD than in patients without
CHD (Table 2). After adjusting for age, sex, dates of
enrollment, employment status, and the region of the United
States, patients with CHD had significantly higher prevalence
risk ratios for all individual comorbid diseases, except for
substance abuse, AIDS, and peptic ulcer, compared with
patients without CHD (Table 2). In an assessment of effect
modification by age, risk ratios for the association of CHD
versus non-CHD with comorbidities were significantly higher
(interaction P<0.05) among younger patients for CHF,
arrhythmias, CAD, hypertension, peripheral vascular disorder,
renal failure, liver disorder, hypothyroidism, and psychiatric
disorders but not for other comorbidities. After adjusting for
the covariates and considering interaction with age, patients
with severe CHD aged <40 years had higher risks of
comorbidities previously recognized to be common in CHD
and noncardiovascular ones but lower risks for cardiovascular
comorbidities than patients with nonsevere CHD (Table 3).
After the age of 40 years, there were higher risks of
“comorbidities previously recognized to be common in CHD,”
lower risks of other cardiovascular comorbidities, and no
Figure 2. Number of comorbidities among patients with congenital heart disease (CHD) and patients
without CHD, stratified by age groups (P<0.001 for all comparisons between patients with CHD and
patients without CHD). Source: IBM MarketScan database, 2010 to 2016.
DOI: 10.1161/JAHA.119.013450 Journal of the American Heart Association 5
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differences in noncardiovascular comorbidities among
patients with severe CHD than patients with nonsevere CHD
(Table 3). The association of severe versus nonsevere CHD
with cardiovascular comorbidities was similar in both age
groups (interaction P=0.27) but differed across age groups for
any (P=0.003), previously recognized in CHD (P<0.001), and
noncardiovascular (P=0.001) comorbidities.
Among all CHD anatomic subgroups, patients with ES had
the highest comorbidity rate of 65.4%. Among individual
comorbidities, patients with ES had the highest rates of CHF
(13.2%), pulmonary circulation disorders (15.1%), stroke
(3.24%), anemia (8.65%), coagulopathy (7.40%), renal disease
(2.43%), and liver disease (6.49%) (Tables 4 and 5). The rate
of arrhythmia (11.8%) was highest in patients with a
common ventricle. The rates of hypertension (31.9%),
hyperlipidemia (13.2%), and peripheral vascular disorder
(11.7%) were highest in patients with aortic anomalies,
whereas those of CAD (6.62%) and diabetes mellitus (9.88%)
were highest in patients with subaortic stenosis (Tables 4
and 5).
Table 2. RRs for Having Individual Comorbid Conditions Among Patients With CHD Versus Patients Without CHD
Comorbidities
% Prevalence CHD vs Non-CHD
CHD Non-CHD Adjusted RR (95% CI)* P Value
Any comorbidity 42.1 23.6 1.58 (1.54–1.63) <0.001
Previously recognized to be common in CHD 8.34 0.66 9.41 (7.99–11.1) <0.001
Congestive heart failure 3.93 0.26 11.9 (9.04–15.7) <0.001
Arrhythmias 3.92 0.31 9.61 (7.61–12.1) <0.001
Pulmonary circulation disorders 2.88 0.17 10.6 (7.82–14.2) <0.001
Other cardiovascular 24.5 12.2 1.73 (1.66–1.80) <0.001
Hypertension 19.0 10.0 1.67 (1.59–1.75) <0.001
Hypercholesterolemia 7.49 3.95 1.61 (1.49–1.73) <0.001
Coronary artery disease 3.13 0.76 3.43 (2.92–4.03) <0.001
Peripheral vascular disease 3.51 0.51 5.35 (4.35–6.57) <0.001
Stroke 1.09 0.15 5.60 (3.92–8.00) <0.001
Noncardiovascular 29.3 17.9 1.47 (1.41–1.52) <0.001
Chronic lung disease 6.52 3.35 1.77 (1.60–1.95) <0.001
Hypothyroidism 6.00 3.23 1.59 (1.45–1.76) <0.001
Obesity 5.64 3.66 1.43 (1.29–1.59) <0.001
Psychiatric 5.59 3.75 1.49 (1.35–1.65) <0.001
Diabetes mellitus 5.13 3.64 1.29 (1.18–1.42) <0.001
Anemia 4.63 2.06 2.11 (1.86–2.38) <0.001
Fluid and electrolyte disorders 3.46 1.25 2.32 (1.99–2.70) <0.001
Neurologic disorders 3.08 0.96 2.62 (2.21–3.11) <0.001
Coagulopathy 1.69 0.30 4.87 (3.64–6.53) <0.001
Liver disorder 1.66 0.66 1.83 (1.48–2.27) <0.001
Any tumor 1.58 0.96 1.41 (1.18–1.69) <0.001
Rheumatoid arthritis 1.49 0.83 1.55 (1.27–1.88) <0.001
Renal failure 1.20 0.36 2.35 (1.82–3.02) <0.001
Weight loss 1.00 0.50 1.68 (1.30–2.18) <0.001
Substance abuse 1.14 0.95 1.02 (0.81–1.27) 0.895
AIDS 0.09 0.04 2.09 (0.81–5.43) 0.126
Peptic ulcer 0.06 0.02 3.99 (0.49–32.4) 0.194
CHD indicates congenital heart disease; RR, risk ratio.
*Models were adjusted for age, sex, dates of enrollment, presence or absence of CHD, beneficiary status, and the US region.
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Discussion
We used a large database containing claims for commercially
insured enrollees to generate population-based estimates of
comorbidity rates among adult patients with CHD within the
United States. When compared with patients without CHD, we
observed that patients with CHD had significantly higher
comorbidity rates than age-, sex-, and dates of enrollment–
matched controls without CHD. After multivariate adjustment,
patients with CHD had 9.41-, 1.73-, and 1.47-fold higher risks
of comorbidities that are previously recognized to be common
in CHD, other cardiovascular, and noncardiovascular comor-
bidities, respectively, than controls without CHD. Among CHD
patients, those with ES had the highest rate of having at least
one comorbid disease and had high rates of CHF, pulmonary
circulation disorders, stroke, anemia, coagulopathy, renal
disorder, liver disorder, and most other noncardiovascular
comorbidities. The rate of arrhythmia was highest in patients
with common ventricle. After adjusting for covariates and
considering interaction with age, patients with severe CHD of
any age had higher risks of comorbidities previously recognized
to be common in CHD and lower risks of other cardiovascular
comorbidities than patients with nonsevere CHD, whereas the
risks of noncardiovascular comorbidities was higher among
patients with severe CHD than patients with nonsevere aged
<40 years but not different after the age of 40 years.
Overall, our estimates of the prevalence of individual
comorbidities in <65-year-old adult patients with CHD were
lower than those observed by Afilalo et al.6 However, Afilalo
et al6 studied an older cohort (aged ≥65 years) of patients with
CHD, which likely contributed to the differences in findings
from our study. Not surprisingly, CHF, arrhythmias, and
pulmonary circulation disorders were much more prevalent
among patients with CHD than patients without CHD in our
study. This is likely caused by the impact of the underlying
congenital lesions in altering the molecular and structural
properties of the heart and lung vasculature. Consequently, the
prevalence of CHF was highest in conditions known to have
significant alteration in their underlying cardiac structure from
prior surgery and hemodynamics, such as ES, common
ventricle, transposition of great arteries, and tetralogy of Fallot.
Similarly, arrhythmia was most prevalent in patients with
common ventricle, followed by ES, transposition of great
arteries, and anomalies of veins. The structural and hemody-
namic changes are also expected to be more pronounced
among patients with severe CHD, which may contribute to the
higher rates of these comorbidities we observed among
patients with severe CHD than among patients with nonsevere
CHD of any age.
We found the rate of CAD in patients with CHD was lower
than the 9.2% reported by Giannakoulas et al in the United
Kingdom26 but higher than the 0.8% observed by Bokma et al
in the Dutch population.27 This may be because Giannakoulas
et al26 reported the CAD rate among hospitalized patients
from a tertiary center in the United Kingdom and included in
their definition of CAD any significant coronary angiography
findings. On the other hand, Bokma et al27 defined CAD as
acute coronary syndrome or those needing revascularization
and, thus, were likely restricted to more severe forms of CAD
than our study. Also, we found that patients with CHD had a
significantly higher prevalence of CAD than patients without
CHD. Bokma et al27 had shown that traditional atheroscle-
rotic risk factors were associated with CAD in adult patients
with CHD.27 Further studies in this area might help to develop
appropriate screening and risk factor modification protocols.
Table 3. Age-Stratified RRs for Having Comorbid Diseases Among Patients With Severe CHD Versus Patients With Nonsevere CHD
Comorbidities
% Prevalence Severe vs Nonsevere CHD
Severe CHD (n=8099)
Nonsevere CHD
(n=14 837) Adjusted RR (95% CI)* P Value
Patients with CHD, aged 18–40 y
Any comorbidity 32.4 28.8 1.16 (1.08–1.24) <0.001
Previously recognized to be common in CHD 9.66 3.13 3.29 (2.75–3.93) <0.001
Other cardiovascular 10.2 12.3 0.84 (0.74–0.96) 0.008
Noncardiovascular 24.2 21.2 1.19 (1.09–1.29) <0.001
Patients with CHD, aged ≥40 y
Any comorbidity 60.0 57.5 1.04 (0.99–1.08) 0.077
Previously recognized to be common in CHD 20.1 9.92 1.96 (1.76–2.19) <0.001
Other cardiovascular 38.8 42.6 0.91 (0.86–0.96) 0.001
Noncardiovascular 39.6 38.6 1.00 (0.94–1.07) 0.939
CHD indicates congenital heart disease; RR, risk ratio.
*Models were adjusted for sex, dates of enrollment, type of CHD, beneficiary status, and the US region.
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Lanz et al found the cumulative risk over 12 years of
ischemic stroke in patients with CHD up to the age of
64 years to be 6.1% in women and 7.7% in men, with another
0.8% of women and 1.3% of men having hemorrhagic
strokes.24 We found a prevalence rate of all types of stroke
to be only 0.92% in our study, but we calculated annual
estimates and did not have 12-year data. Although it is not
clear what the stroke rate would have been had we been able
to follow our population for 12 years, the annual rate we
found is only a little higher than that observed by Lanz et al.24
Prior investigators from the Netherlands have shown that the
risk factors of ischemic stroke in patients with CHD are less
likely to be traditional atherosclerotic risk factors and more
likely to be factors related to their underlying congenital
lesions.27 This is further supported by the fact that the
highest risk of stroke was found among patients with ES,
endocardial cushion, truncus, and common ventricle, in whom
hyperviscosity, shunts, valvular disease, and passive blood
flow are known pathophysiological risk factors for throm-
boembolism and stroke.
The rates of hypertension within the adult population with
CHD found in our study was lower than the rates reported in
prior studies, which ranged from 24% to 38.7%.8–10 Similarly,
we found lower rates of hyperlipidemia, obesity, and diabetes
mellitus than observed in these studies. It is possible that the
higher rates of these comorbidities reported in prior studies
reflects referral bias and sicker patients because each of
those studies involved patients from a single tertiary center,
whereas our study sample was drawn from a commercially
insured population. In addition, those studies had much
smaller sample sizes than the present study. However, similar
to a prior UK study, the risks of the comorbidities related to
atherosclerotic risks were higher in patients with CHD than in
patients without CHD.14 Also, among the CHD lesions, these
comorbidities were much more prevalent in the patients with
nonsevere CHD (like those with aortic anomalies and
subaortic stenosis), who were older. The risks of the
cardiovascular comorbidities remained higher for patients
with nonsevere CHD than patients with severe CHD, aged <40
or ≥40 years, which suggests that preventive measures for
Table 4. Lesion-Specific Prevalence Risks (%) for Having All Cardiovascular Comorbid Conditions
Variable
Previously Recognized to Be Common in
CHD Other Cardiovascular
CHF Arrhythmias Pulm Circ Hypertension Hyperlipidemia CAD PVD Stroke
Severe CHD 6.69 6.27 4.32 13.5 5.81 2.79 2.72 1.49
Eisenmenger syndrome 13.2 10.3 15.7 22.2 8.92 6.49 7.84 3.24
HLHS 8.47 6.18 3.20 15.1 6.64 2.75 2.52 1.60
Common ventricle 9.70 11.8 3.28 7.85 3.00 2.43 2.14 1.57
TGA 8.64 7.29 3.25 12.6 4.32 2.22 1.98 1.07
TOF 6.61 5.34 4.30 12.6 5.10 2.49 3.14 0.72
Truncus arteriosus 3.18 4.54 4.08 17.9 8.17 3.78 3.63 2.87
Endocardial cushion defect 3.89 5.34 4.30 15.0 8.00 3.19 1.96 2.59
Nonsevere CHD 2.75 2.92 2.27 21.4 8.21 3.27 3.85 0.92
Ebstein anomaly 3.82 5.12 2.37 17.5 6.42 2.75 1.68 0.46
Aortic coarctation 2.27 2.31 1.13 27.1 7.05 2.87 7.01 0.44
Anomalies of the pulmonary artery 3.12 3.40 4.62 23.2 8.83 2.72 2.99 0.54
Anomalies of the pulmonary valve 1.97 1.35 2.16 17.1 6.94 3.07 2.59 0.44
Anomalies of the tricuspid valve 2.64 4.49 2.11 20.6 8.44 2.64 1.85 0.79
Ventricular septal defect 2.94 2.87 2.68 18.6 7.90 2.94 2.49 1.02
Patent ductus arteriosus 1.83 1.78 2.25 17.9 8.06 3.04 2.83 2.04
Anomalies of veins 2.53 6.96 3.16 21.0 8.54 3.32 2.69 1.58
Unspecified defect of septal closure 2.37 3.48 1.74 29.3 12.9 5.85 2.69 1.58
Subaortic stenosis 5.72 5.27 3.03 30.1 11.9 6.62 4.04 1.23
Aortic anomalies 2.78 3.69 0.97 31.9 13.2 5.50 11.7 0.91
Non-CHD 0.26 0.31 0.17 10.0 3.95 0.76 0.51 0.15
CAD indicates coronary artery disease; CHD, congenital heart disease; CHF, congestive heart failure; HLHS, hypoplastic left heart syndrome; Pulm Circ, pulmonary circulation disorders;
PVD, peripheral vascular disease; TGA, transposition of great arteries; TOF, tetralogy of Fallot.
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atherosclerotic disease could be an important area of focus in
CHD clinics, especially for those with nonsevere lesions. It has
been shown that eligible adults with CHD at large tertiary
adult CHD centers in the United States are less likely to
receive statin or primary cancer screening compared with
adults without CHD.10,28 This underscores that maybe CHD
clinicians need to develop close partnerships with primary
care physicians, including education of primary care providers
of the need for screening.
Our rates of noncardiovascular conditions were lower than
the 95% prevalence reported in a tertiary center cohort in
Germany.29 This is likely because different comorbidities were
included within the noncardiovascular comorbidity category
between the 2 studies, and our study was based on a
commercially insured subset of the entire population rather
than at a tertiary center. Within a national US inpatient data
set, Rodriguez et al30 found a much higher rate of renal failure
in patients with CHD, ranging from 3.4% to 18.8%, depending
on the chronicity of renal disease and presence or absence of
heart failure, than our observations, but this again was a
sample of hospitalized patients. The noncardiovascular
comorbidities are the ones for which patients with CHD are
more likely to be seen by internists or noncardiology
specialists. A multicenter study from Germany found that
63% of inpatient adult CHD emergencies required manage-
ment by a specialist other than a cardiologist.31 Clinicians
caring for CHD might thus consider using a multidisciplinary
approach, including building close collaborations with inter-
nists and specialists to help provide appropriate care for the
noncardiovascular comorbidities we found to be prevalent
among patients with CHD. This could be similar to the prior
efforts to bring together subspecialty experts from various
Table 5. Lesion-Specific Prevalence Risks (%) for Having Selected Noncardiovascular Comorbid Conditions (10 Most Frequent
Conditions and Renal Failure)
Variable
Chronic Lung
Disease Hypothyroidism Obesity
Psychiatric
Disease DM Anemia Lytes
Neurologic
Disease Coagulopathy
Liver
Disease
Renal
Disease
Severe CHD 6.07 6.49 4.91 5.52 4.32 4.40 3.80 4.14 2.45 2.20 1.34
Eisenmenger syndrome 13.5 10.0 5.14 8.92 7.03 8.65 12.70 10.3 7.30 6.49 2.43
HLHS 5.26 4.35 3.43 7.09 3.66 4.81 6.64 5.03 2.75 4.35 3.43
Common ventricle 4.42 6.42 2.85 4.42 3.00 3.85 4.99 4.85 3.99 5.71 1.71
TGA 4.79 3.80 4.24 4.83 3.41 2.85 3.13 3.17 1.70 1.70 1.19
TOF 5.82 5.69 4.43 5.13 4.30 3.84 3.56 3.60 2.44 1.83 1.33
Truncus arteriosus 7.87 7.26 6.81 8.17 5.45 5.90 2.72 5.30 3.18 3.18 1.51
Endocardial cushion
defect
6.78 10.0 6.63 5.74 5.00 5.93 3.11 4.52 1.85 1.22 0.89
Nonsevere CHD 6.71 5.80 5.96 5.63 5.48 4.73 3.31 2.62 1.37 1.43 1.14
Ebstein anomaly 5.20 8.49 6.04 7.65 4.13 4.97 2.91 2.29 1.15 1.30 1.22
Aortic coarctation 5.77 3.94 4.72 4.57 3.50 3.27 2.79 2.01 1.01 0.86 0.80
Anomalies of the
pulmonary artery
12.9 8.15 10.2 6.79 6.93 6.11 4.35 3.53 2.31 2.17 1.77
Anomalies of the
pulmonary valve
7.09 5.33 5.96 5.85 4.93 5.15 3.43 2.19 0.91 1.46 0.95
Anomalies of the
tricuspid valve
6.60 6.07 4.22 5.28 6.07 6.33 3.17 3.17 1.06 2.64 1.58
Ventricular septal defect 6.44 5.93 5.48 5.20 5.47 4.66 3.17 2.58 1.42 1.18 1.04
Patent ductus arteriosus 6.81 5.34 5.65 6.34 5.76 5.03 2.88 2.58 1.41 1.88 1.26
Anomalies of veins 7.91 5.70 6.96 6.80 6.49 5.85 5.06 4.59 2.69 4.27 1.11
Unspecified defect of
septal closure
9.02 10.28 8.23 8.70 9.49 6.01 6.17 3.48 0.79 1.58 1.11
Subaortic stenosis 8.75 7.97 11.1 8.08 9.88 6.29 4.38 3.37 1.68 2.13 1.91
Aortic anomalies 6.71 5.38 7.92 5.74 7.85 5.50 3.75 2.72 2.11 2.30 2.30
Non-CHD 3.35 3.24 3.66 3.75 3.64 2.06 1.25 0.96 0.30 0.66 0.36
CHD indicates congenital heart disease; DM, diabetes mellitus; HLHS, hypoplastic left heart syndrome; Lytes, fluid and electrolyte abnormalities; TGA, transposition of great arteries; TOF,
tetralogy of Fallot.
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disciplines to initiate a formal evaluation of liver disease that
is prevalent among single-ventricle patients after Fontan
palliation.32
In summary, our overall estimates of the comorbidities
were lower than expected from other publications, but our
study sample was drawn from a commercially insured
outpatient population and did not have tertiary center bias.
Furthermore, there might be selection bias related to who is
included in a commercially insured database, as these
individuals generally are healthier and expected to have
higher socioeconomic status than those without insurance or
those insured by Medicaid. Thus, our estimates provide
preliminary information about the care delivery model neces-
sary to optimize care for patients with CHD but should be
supplemented by analyses from the 51% of the US population
who uses other types of insurance, including government
programs. Nonetheless, these adult patients with CHD had
significantly higher comorbidity burden than their peers,
suggesting they have higher risks and thus need to be
managed differently. The medical community at large need to
recognize their unique healthcare needs, including the high
burden of non–cardiovascular-related diagnoses that may
mimic or be affected by coexisting CHD.
Limitations
This study has several limitations. First, ICD 9 and ICD 10
codes have imperfect sensitivity and specificity, and CHD may
have been incorrectly coded. Where possible, however, we
used the codes that have been previously validated and
removed the ones that were nonspecific. Misclassification of
comorbidities also can be a potential source of error, but that
would be random and bias the results toward the null. Second,
we did not use the recently published physiologic parameters
to assign the severity of CHD lesions because most of those
parameters are based on detailed clinical and/or imaging
data,33 which are not present in claims databases. Finally,
patients carrying a diagnosis of CHD are expected to have
more contact with the healthcare system and to be seen
regularly by cardiovascular specialists; thus, they may be
screened more frequently for some of the comorbidities.
Conclusions
The present study uses a large database containing claims for
commercially insured enrollees to generate population-based
estimates of comorbidity rates for 40 000 adults with CHD.
Patients with CHD had 9.41-, 1.73-, and 1.47-fold higher risks
of comorbidities previously recognized to be common in CHD,
other cardiovascular, and noncardiovascular ones when
compared with patients without CHD, after adjusting for the
baseline characteristics. Among patients with CHD, those
with ES had the highest prevalence of comorbidities. After
considering interaction with age, patients with severe CHD of
any age had higher risks of comorbidities previously recog-
nized to be common in CHD and lower risks of other
cardiovascular conditions than patients with nonsevere CHD,
whereas the risks of noncardiovascular comorbidities was
higher among patients with severe CHD before the age of 40
years but similar after the age of 40 years than patients with
nonsevere CHD. These data could be used to plan for the
clinical resources patients with CHD are likely to need.
Clinicians caring for CHD may want to use a multidisciplinary
approach to the evaluation and management of these
patients, including building close collaborations with internists
and noncardiology specialists to help provide patients appro-
priate screening and preventive care.
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